Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines
{{output}}
Background: Adjuvant systemic therapy has improved breast cancer outcomes over the past decades. Following the distinction of molecular subtypes and the introduction of gene expression profiling and prognostic tools, chemotherapy... ...
